GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01196039
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01186991
- Locations
- 🇺🇸
Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-02
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01173536
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2012-12-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT01163747
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- Conditions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01160250
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01160861
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01139723
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT01125748
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01122875
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01120561
- Locations
- 🇺🇸
Investigational Site, Seattle, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath